Propanc Biopharma, Inc. PPCB
used in this Annual Report on Form 10-K, references to the "Company," "Propanc," "we," "our,"
and "us" refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated. In addition, references
to our "financial statements" are to our consolidated financial statements included elsewhere in this Annual Report on Form
10-K except as the context otherwise requires.
Last close
1.01
2026-09-04
Market cap
$57.5M
2026-03-31 share count
52-week range
0.95 - 62.50
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-371.22
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | — | — | — | — | — | — | $28.1K | $30.5K | $29.0K | — |
| R&D | $223.7K | $248.1K | $247.9K | $256.1K | $231.0K | $180.0K | $260.3K | $1.8M | $971.8K | $1.4M |
| SG&A | $57.0M | $1.3M | $1.5M | $1.7M | $1.6M | $3.3M | $2.3M | $2.1M | $4.7M | $5.4M |
| Total operating expenses | $57.3M | $1.5M | $1.8M | $2.0M | $1.8M | $3.5M | $2.6M | $4.0M | $5.7M | $6.9M |
| Operating income | -$57.3M | -$1.5M | -$1.8M | -$2.0M | -$1.8M | -$3.5M | -$2.6M | -$4.0M | -$5.7M | -$6.9M |
| Interest expense | $563.8K | $665.8K | $532.8K | $568.8K | $449.5K | $1.7M | $1.3M | $2.8M | $3.2M | $4.5M |
| Pre-tax income | -$58.9M | -$1.9M | -$2.8M | -$2.7M | -$2.1M | -$4.9M | -$5.8M | -$7.0M | -$7.6M | -$9.3M |
| Income tax | — | $129.1K | $129.8K | $55.0K | $113.4K | $134.7K | $115.4K | $179.3K | $305.7K | $72.5K |
| Net income | -$58.9M | -$1.8M | -$2.7M | -$2.7M | -$2.0M | -$4.7M | -$5.8M | -$7.0M | -$7.9M | -$9.4M |
| EPS, basic | -371.22 | -35,324.35 | -1.80 | -49.23 | -0.80 | — | — | — | — | — |
| EPS, diluted | -371.22 | -35,324.35 | -1.80 | -49.23 | -0.80 | -192.45 | -10.97 | -178.75 | -2.24 | -4.83 |
| Shares, diluted (wtd. avg.) | $158.7K | $57 | $1.7M | $68.2K | $3.0M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | $4.1K | $2.3K | $67.0K | — | — | — | — |
| Total current assets | $8.4M | $25.4K | $19.0K | $15.0K | $6.6K | $69.0K | $91.1K | $60.9K | $82.0K | $362.8K |
| Property, plant and equipment | — | — | $302 | $2.0K | $4.3K | $5.7K | $8.4K | $8.3K | $10.8K | $12.5K |
| Total assets | $19.6M | $72.4K | $60.3K | $81.7K | $13.1K | $98.5K | $101.7K | $71.4K | $95.1K | $379.1K |
| Accounts payable | $1.2M | $1.2M | $966.7K | $943.0K | $1.0M | $842.2K | $917.3K | $1.2M | $483.5K | $50.0K |
| Total current liabilities | $5.6M | $3.8M | $3.2M | $3.1M | $3.1M | $3.7M | $4.4M | $6.8M | $5.5M | $2.9M |
| Long-term debt | $537.9K | $399.3K | $390.5K | $926.4K | $624.6K | $1.6M | $1.7M | $4.7M | $3.5M | $1.2M |
| Total liabilities | $5.7M | $3.9M | $3.2M | $3.1M | $3.1M | $3.7M | $4.4M | — | — | — |
| Retained earnings | -$125.6M | -$66.7M | -$64.7M | -$61.6M | -$58.2M | -$55.8M | -$51.0M | -$45.3M | -$38.2M | -$30.4M |
| Total equity | $13.9M | -$3.8M | -$3.1M | -$3.0M | -$3.1M | -$3.6M | -$4.3M | -$6.8M | -$5.4M | -$2.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$405.2K | -$935.1K | -$1.1M | -$1.4M | -$1.1M | -$1.8M | -$2.1M | -$2.2M | -$2.1M | -$4.5M |
| Depreciation and amortisation | — | $297 | $1.7K | $2.0K | $2.0K | $2.5K | $2.3K | $2.2K | $2.2K | $877 |
| Stock-based compensation | $4.6M | — | $2.4K | $72.5K | $82.9K | $300.4K | — | $516.1K | $1.7M | $1.7M |
| Capital expenditure | — | — | — | — | — | — | $2.9K | — | — | $9.9K |
| Investing cash flow | — | — | — | — | — | — | -$2.9K | — | — | -$9.9K |
| Financing cash flow | $490.8K | $941.9K | $1.1M | $1.5M | $1.1M | $1.9M | $2.1M | $2.4M | $2.1M | $4.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-033807.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |